ZEISS Webinar Series

TARGIT-A study long-term outcomes for breast cancer

Targeted intra-operative single dose radiotherapy (TARGIT-A)

Long-term study results show non-inferiority of immediate TARGIT-IORT compared to external beam radiotherapy (EBRT) as well as similar risk of local tumor recurrence in the breast and reduced non-breast cancer death.

TARGIT-A is currently the largest multicenter randomized clinical trial with one accelerated partial breast irradiation (APBI) technique in the field of Partial Breast Irradiation. The academic study was supervised by the independent steering committee of the National Institute for Health Research (NIHR).
Between 2000 and 2012, 2998 patients aged 45 and older with invasive ductal carcinoma were randomized in 32 centers from 10 countries and treated with INTRABEAM®. Over this time, 1140 women received TARGIT-IORT and a control group of 1158 women received the standard EBRT treatment.

With the now available long-term study outcomes the effectiveness and efficiency of targeted intra-operative single dose radiotherapy for early stage breast cancer patients is confirmed.


Long-term results of TARGIT-A trial – Background & Update

What did it take to achieve to show the non-inferiority of TARGIT-A?

Join us in hearing from Professor Vaidya the first time in a live webinar when he presents the new long-term outcomes from the international TARGIT-A breast cancer study. "Single dose intra-operative radiotherapy for early stage breast cancer can be a better alternative to conventional whole breast radiotherapy for most patients during primary tumor management " stated principal investigator Professor Jayant Vaidya.

Date & Time:

Tuesday, September 22, 2020
9:00 - 10:00 AM CEST | 3:00 - 04:00 AM EDT
4:00 - 5:00 PM CEST | 10:00 - 11:00 AM EDT

About the Speaker

Prof. Jayant Vaidya, MBBS, MS, DNB, FRCS, PhD
Professor of Surgery and Oncology and Scientific Director at University College London (UK),
Chief Principal Investigator of the TARGIT-A trial


Long-term results of TARGIT-A trial – Radiation advantages & drawbacks

“These excellent results provide real clinical justification for single intraoperative radiation in suitable patients with early breast cancer. It is now essential to develop the corresponding treatment guidelines as soon as possible” says joint initiator of the TARGIT-A trial Professor Jeffrey Tobias. Will this method simplify the radiation treatment for early breast cancer?

Join us in hearing Professor Tobias discussing the efficiency of targeted intra-operative radiotherapy (TARGIT) as a single dose.

Date & Time:

Wednesday, September 30, 2020

9:00 - 10:00 AM CEST | 3:00 - 04:00 AM EDT
4:00 - 5:00 PM CEST | 10:00 - 11:00 AM EDT

About the Speaker

Prof. Jeffrey Tobias
Professor of Oncology at University College London (UK) and joint initiator of the TARGIT-A study


Long-term results of TARGIT-A trial – Deep-dive into the results

Do you know the top ranked long-term accelerated partial breast irradiation (APBI) study completeness wise?

TARGIT-A is currently the largest multicenter randomized clinical trial in the field of Partial Breast Irradiation with one technique and meets the highest scientific standards. Learn more and join us in hearing the statistician of the TARGIT-A trial Professor Max Bulsara.

Date & Time:

Wednesday, October 7, 2020
9:00 - 10:00 AM CEST | 3:00 - 04:00 AM EDT
4:00 - 5:00 PM CEST | 10:00 - 11:00 AM EDT

About the Speaker

Prof. Max Bulsara, PhD, MSc, BSc
Professor and Chair of Biostatistics at University of Notre Dame, Australia and Statistician of the TARGIT-A trial


Effectiveness, efficiency and highest scientific standards – the TARGIT-A trial comparing single-dose IORT with EBRT upheld expectations

The use of targeted intra-operative radiotherapy (TARGIT), as a single dose – with ZEISS INTRABEAM – directly after removal of a tumor, is confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). The TARGIT-A study further is the largest international multicenter study with a follow-up time of 8.6 years. In addition to its effectiveness, the IORT technique is demonstrating its cost efficiency. But will this be enough to now also develop further clinical treatment standards and reflect this in the guidelines?

Please join us in hearing the breast surgeon Professor Michael Alvarado, the radiation oncologists Professor William Small and Dr. Valery Uhl discussing this elemental question, based on this latest clinical milestone.

Date & Time:

Tuesday, October 13, 2020
9:00 - 10:00 AM CEST | 3:00 - 04:00 AM EDT
4:00 - 5:00 PM CEST | 10:00 - 11:00 AM EDT

About the Speaker

Prof. Michael Alvarado, MD
Professor of Surgery and Director Breast Surgery Oncology Fellowship at UCSF Health, San Francisco, USA

Prof. William Small, Jr., MD, FARCO, FACR, FASTRO
Professor of Radio-oncology at Loyola University, Chicago, USA

Dr. Valery Uhl, MD  
Board Certified Radiation Oncologist trained at UCSF, San Francisco, USA and
President of the TARGIT Collaborative Group (TCG)


Register for the Webinar

Unable to load form.

The statements of the speakers reflect only their personal opinions and do not necessarily reflect the opinions of any institution with which they are affiliated. The speakers have a contractual or other financial relationship with Carl Zeiss Meditec AG and Carl Zeiss Meditec, Inc. and its affiliates and have received financial support.